Advertisement

Remission Induction and Maintenance Modalities in Acute Myeloid Leukemia: A Multicenter Randomized Study

  • M. Marty
  • E. Lepage
  • H. Guy
  • D. Bordessoule
  • B. Desablens
  • J. L. Harousseau
  • F. Guilhot
  • G. Leverger
  • G. Schaison
  • M. Boiron
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

While both remission rates and duration have improved in acute myeloid leukemia (AML), the overall prognosis remains poor. Large multicenter studies using DAT or DAT-derived remission induction regimens have failed to reproduce the complete remission (CR) rates (75%–85%) obtained in small single-institution studies [1–3]. Maintenance therapy has been demonstrated to improve CR duration [4, 5]; yet ultimately, less than 20% of all treated patients will achieve long-term disease-free survival (DFS) [6–8]. Furthermore, modalities of maintenance regimens remain debated: while both early intensification and semicontinuous maintenance therapy have improved DFS in large studies [4, 8, 9], they carry drug-related lethal toxicity in 5%–10% of patients [8–11]. Prognostic factors that could affect both indications and modalities of therapy are still poorly understood in AML, thus preventing the design of more specific treatment.

Keywords

Acute Myeloid Leukemia Remission Duration Remission Induction Therapy Maintenance Modality Early Intensification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rees JKH, Sandler RM, Challenger J, et al. (1977) Treatment of acute myeloid leukemia with a triple cytotoxic regimen: DAT. Br J Cancer 36: 770–776CrossRefGoogle Scholar
  2. 2.
    Gale RP, Foon KA, Cline MJ, et al. (1981) Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 94: 753–757PubMedGoogle Scholar
  3. 3.
    Peterson BA, Bloomfield CD, Bosl GJ, et al. (1980) Intensive five-drug combination chemotherapy for adult acute nonlymphocytic leukemia. Cancer 46: 663–668PubMedCrossRefGoogle Scholar
  4. 4.
    Bloomfield CD (1985) Postremission therapy in acute myeloid leukemia. J Clin Oncol 3: 1570–1572PubMedGoogle Scholar
  5. 5.
    Vaughan WP, Karp JE, Burke PJ (1984) Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64: 975–980PubMedGoogle Scholar
  6. 6.
    Rai KR, Holland JF, Glidewell OJ, et al. (1981) Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 58: 1203–1212PubMedGoogle Scholar
  7. 7.
    Mertelsmann R, Moore MAS, Clarkson B (1982) Leukemia cell phenotype and prognosis: an analysis of 519 adults with acute leukemia. Blood Cells 8: 561–583PubMedGoogle Scholar
  8. 8.
    Buchner T, Urbanitz D, Hiddermann W, et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the german AML cooperative group. J Clin Oncol 3: 1583–1589PubMedGoogle Scholar
  9. 9.
    Rees JKH, Gray R, Hayhoe FCJ (1985) Late intensification therapy in the treatment of acute myeloid leukemia. Proc Am Soc Clin Oncol 4: 160 (abstract)Google Scholar
  10. 10.
    Keating MH, Smith TL, McCredie KB, et al. (1981) A four-year experience with anthracycline, cytosine arabinoside, vincris tine and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779–2788PubMedCrossRefGoogle Scholar
  11. 11.
    Champlin R, Jacobs A, Gale RP, et al. (1984) Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. Lancet I: 894–896CrossRefGoogle Scholar
  12. 12.
    Marty M, Ferme C, Schaison G, et al. (1982) 16LA79 in ANLL: therapeutic value of high doses Ara-C-rubidazone in remission induction regimen. 3rd International Symposium on therapy of acute leukemias, Rome, p 326Google Scholar
  13. 13.
    Boiron M, Jacquillat C, Marty M, et al. (1981) Anthracyclines in the treatment of acute nonlymphocytic leukemias. Cancer Treat Rep 65: 73–76PubMedGoogle Scholar
  14. 14.
    Kaplan E, Meier 0 (1979) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481Google Scholar
  15. 15.
    Peto R, Pike MC, Armitage P, et al. (1977) Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39PubMedCrossRefGoogle Scholar
  16. 16.
    Marty M, Ganem G, Fisher J, et al. (1984) Leucemie aigue promyelocytaire etude retrospective de 119 malades traites par Daunorubicine. Nouv Rev Fr Hematol 26: 371–378PubMedGoogle Scholar
  17. 17.
    Janvier M, Tobelem G, Daniel MT, et al. (1984) Acute monoblastic leukemia. Clinical, biological data and survival in 45 cases. Scand J Haematol 32: 385–390PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • M. Marty
    • 1
  • E. Lepage
  • H. Guy
  • D. Bordessoule
  • B. Desablens
  • J. L. Harousseau
  • F. Guilhot
  • G. Leverger
  • G. Schaison
  • M. Boiron
  1. 1.Institut de Recherches sur les Leucemies et les Maladies du SangHop Saint LouisParisFrance

Personalised recommendations